Surface Refractive Index Shift of Kalifilcon A Compared With Dailies Total1 and Precision1 Lenses
Completed · Not applicable
Conditions studied: Contact Lens Wear
In brief
This was a single-site, bilateral, repeated-measures insertion study in habitual soft contact lens wearers. Ten participants were enrolled. All participants attended a Screening/Dispensing Visit at which informed consent was obtained and eligibility was assessed. Eligible participants then wore each of three commercially available daily disposable soft contact lens types - kalifilcon A (Bausch + Lomb), Dailies Total1 (delefilcon A, Alcon) and Precision1 (verofilcon A, Alcon), all -3.00 D - bilaterally for wear times of 0.5, 1, 3, 5 and 10 minutes over a total of 6 study visits. A new lens pair was inserted for each wear time, with a 3-5 minute washout period between lens pairs. Immediately following removal, the right-eye lens was measured for surface refractive index on a Metricon M-2010 Prism Coupler.
Key facts
- Study ID
- NCT04840563
- Run by
- Bausch & Lomb Incorporated
- People needed
- 10
- Starts
- 2021-04-07
- Expected to finish
- 2021-04-15
- Last updated by the study team
- 2026-08-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Be 18 years or older and have full legal capacity to volunteer.
- Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
- Have no active ocular disease or allergic conjunctivitis.
- Not be using any topical ocular medications.
- Be willing and able to follow instructions.
- Have signed a statement of informed consent.
You may not qualify if…
- Participating in a conflicting study in the opinion of the Investigator.
- Considered by the Investigator to not be a suitable candidate for participation.
Where it is running
- Bausch & Lomb Incorporated — Rochester, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.